For individuals facing Transthyretin Amyloid Cardiomyopathy (ATTR-CM), a serious condition, the introduction of Vyndamax and Tafamidis meglumine represents a significant breakthrough . These innovative therapies stabilize the transthyretin protein, preventing its destructive build-up and alleviat